Equities research analysts expect Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Rating) to report earnings per share of ($0.45) for the current quarter, Zacks reports. Two analysts have made estimates for Aquestive Therapeutics’ earnings. The highest EPS estimate is ($0.44) and the lowest is ($0.46). Aquestive Therapeutics reported earnings of ($0.41) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 9.8%. The business is scheduled to report its next quarterly earnings results after the market closes on Monday, January 1st.
According to Zacks, analysts expect that Aquestive Therapeutics will report full-year earnings of ($1.65) per share for the current fiscal year, with EPS estimates ranging from ($1.88) to ($1.41). For the next year, analysts anticipate that the firm will post earnings of ($0.68) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Aquestive Therapeutics.
Aquestive Therapeutics (NASDAQ:AQST – Get Rating) last posted its quarterly earnings results on Tuesday, March 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.01). The firm had revenue of $11.08 million during the quarter, compared to analyst estimates of $9.81 million. During the same quarter in the prior year, the company earned ($0.60) EPS.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Graypoint LLC acquired a new stake in shares of Aquestive Therapeutics in the 1st quarter valued at about $1,080,000. BlackRock Inc. raised its holdings in Aquestive Therapeutics by 5.3% during the fourth quarter. BlackRock Inc. now owns 348,366 shares of the company’s stock worth $1,354,000 after acquiring an additional 17,420 shares in the last quarter. Virtu Financial LLC bought a new stake in Aquestive Therapeutics during the fourth quarter worth about $308,000. Schonfeld Strategic Advisors LLC bought a new stake in Aquestive Therapeutics during the fourth quarter worth about $411,000. Finally, Millennium Management LLC raised its holdings in Aquestive Therapeutics by 10.8% during the fourth quarter. Millennium Management LLC now owns 358,875 shares of the company’s stock worth $1,396,000 after acquiring an additional 35,101 shares in the last quarter. 38.98% of the stock is currently owned by hedge funds and other institutional investors.
AQST stock traded up $0.01 during midday trading on Monday, hitting $1.41. 3,395 shares of the company’s stock were exchanged, compared to its average volume of 391,671. The stock’s fifty day moving average price is $2.44 and its 200-day moving average price is $3.70. The company has a market cap of $58.47 million, a PE ratio of -0.77 and a beta of 3.30. Aquestive Therapeutics has a one year low of $1.32 and a one year high of $6.40.
Aquestive Therapeutics Company Profile (Get Rating)
Aquestive Therapeutics, Inc, a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
- Get a free copy of the StockNews.com research report on Aquestive Therapeutics (AQST)
- onsemi Is A Deep-Value In The Chip Sector
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.